Analyst consensus rating
Lakewood-Amedex Biotherapeutics Analyst Rating: none
LABT is rated none by 1 analysts with a $12.00 target. As of 2026-08-23.
Direct answer
Lakewood-Amedex Biotherapeutics's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.00.
Forecast evidence checked August 23, 2026.
Get free Lakewood-Amedex Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.24
- Average price target
- $12.00
- High price target
- $12.00
- Low price target
- $12.00
- Low target gap
- +435.7%
- Target upside
- +435.7%
- High target gap
- +435.7%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics has a verified none consensus. The same dataset has an average price target of $12.00.
How far are Lakewood-Amedex Biotherapeutics's low and high targets from the recorded price?
The low target implies +435.7%, while the high target implies +435.7%.
How many analysts are included in Lakewood-Amedex Biotherapeutics's consensus?
The verified consensus includes 1 analysts.
How is Lakewood-Amedex Biotherapeutics's target upside or downside calculated?
The average target of $12.00 is divided by the recorded price of $2.24, then one is subtracted to produce +435.7%. This does not guarantee a future return.
When was Lakewood-Amedex Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.